NASDAQ:PACB - Pacific Biosciences of California Stock Price, Forecast & News

Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB."

Pacific Biosciences of California (NASDAQ:PACB) issued its quarterly earnings results on Thursday, November, 7th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.15) by $0.04. The biotechnology company had revenue of $21.92 million for the quarter, compared to the consensus estimate of $28.02 million. Pacific Biosciences of California had a negative return on equity of 136.85% and a negative net margin of 139.22%. View Pacific Biosciences of California's Earnings History.

Pacific Biosciences of California is scheduled to release their next quarterly earnings announcement on Thursday, February 6th 2020. View Earnings Estimates for Pacific Biosciences of California.

Pacific Biosciences of California will be holding an earnings conference call on Thursday, February 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

3 Wall Street analysts have issued 12-month target prices for Pacific Biosciences of California's stock. Their forecasts range from $7.00 to $8.00. On average, they anticipate Pacific Biosciences of California's share price to reach $7.67 in the next year. This suggests a possible upside of 54.3% from the stock's current price. View Analyst Price Targets for Pacific Biosciences of California.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacific Biosciences of California in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Pacific Biosciences of California.

News stories about PACB stock have trended very negative on Wednesday, InfoTrie Sentiment reports. The research group scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Pacific Biosciences of California earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term. View News Stories for Pacific Biosciences of California.

Pacific Biosciences of California saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 20,380,000 shares, an increase of 7.5% from the December 15th total of 18,960,000 shares. Based on an average daily volume of 2,100,000 shares, the short-interest ratio is currently 9.7 days. Currently, 14.7% of the shares of the stock are short sold. View Pacific Biosciences of California's Current Options Chain.

Some companies that are related to Pacific Biosciences of California include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Rad Laboratories (BIO), PerkinElmer (PKI), BIO-TECHNE (TECH), Bruker (BRKR), Charles River Laboratories Intl. (CRL), Cambrex (CBM), Luminex (LMNX), Fluidigm (FLDM), Harvard Bioscience (HBIO) and aTyr Pharma (LIFE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacific Biosciences of California investors own include Illumina (ILMN), FireEye (FEYE), Novavax (NVAX), CenterPoint Energy (CNP), Gilead Sciences (GILD), Netflix (NFLX), Sangamo Therapeutics (SGMO), Pfizer (PFE), Alkaline Water (WTER) and Exelixis (EXEL).

Pacific Biosciences of California's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Alpine Global Management LLC (0.04%) and Ballentine Partners LLC (0.01%). Company insiders that own Pacific Biosciences of California stock include James Michael Phillips, Kathy Ordonez, Michael Hunkapiller and Susan K Barnes. View Institutional Ownership Trends for Pacific Biosciences of California.

PACB stock was sold by a variety of institutional investors in the last quarter, including Alpine Global Management LLC. Company insiders that have sold Pacific Biosciences of California company stock in the last year include James Michael Phillips, Kathy Ordonez, Michael Hunkapiller and Susan K Barnes. View Insider Buying and Selling for Pacific Biosciences of California.

PACB stock was bought by a variety of institutional investors in the last quarter, including Ballentine Partners LLC. View Insider Buying and Selling for Pacific Biosciences of California.

Shares of PACB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PACB stock can currently be purchased for approximately $4.97.

Pacific Biosciences of California has a market capitalization of $760.24 million and generates $78.63 million in revenue each year. The biotechnology company earns $-102,560,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis. Pacific Biosciences of California employs 401 workers across the globe.View Additional Information About Pacific Biosciences of California.

The official website for Pacific Biosciences of California is http://www.pacb.com/.

Pacific Biosciences of California's mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-521-8000 or via email at [email protected]